Our lead product candidate is a next-generation COVID-19 vaccine with game-changing potential.

 

A Novel Solution for a Global Crisis

In order to help address the pandemic, our founding scientists utilized their expertise with APMV to create our NDV-HXP-S vaccine candidate quickly and efficiently.

In Phase 1/2 clinical studies, our solution performed as well as the leading Pfizer/BioNtech vaccine and outperformed the AstraZeneca vaccine, while offering a myriad of advantages over both.*†

*Comparisons were based on matched samples. †Supporting Evidence

↓

 

Why is our next-generation COVID-19 vaccine better than what’s currently on the market?

  • Successfully induces a mucosal response

  •  Includes spike protein with superior antigen design

  • Consists of 6 prolines instead of 2 prolines - like in other marketed vaccines

  • Design holds spike protein firmly in pre-fusion conformation, leading to more efficient induction of neutralizing antibodies

  • Scientifically, live CVAX-01 is designed to deliver reduced rates of breakthrough infections

 

A Robust Pipeline 

We currently have multiple COVID-19 products in Phase 2 through Emergency Use Authorization, while we’re simultaneously developing a bivalent mucosal RSV+ HMPV vaccine and a mucosal Norovirus vaccine.


 

Preparing for the Next Global Pandemic 

Ultimately, our technology will enable the world to more quickly and effectively prepare for the next pandemic by efficiently engineering NDV to express antigenetic proteins native to a wide range of endemic and emerging viruses (primary examples listed for illustration).

 

  •  COVID-19 (SARS-CoV-2)

  • Respiratory Syncytial Virus (RSV)

  • Human Metapneumovirus (HMPV)

  • Cytomegalovirus (CMV)

  • Hepatitis B Virus (HBV)

  • Hepatitis C Virus (HCV)

  • Arenaviruses (including Lassa Virus)

  • Filoviruses (including Ebola Virus)

  • Nipah Virus

  • Hendra Virus

  • Chikungunya Virus (CHIKV)

  • Rift Valley Fever Virus

  • Hantavirus

  • Highly Pathogenic Avian Influenza Virus